Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Cambridge, MA

Affinivax is advancing a next generation technology platform to enable the development of vaccines and immunotherapies. Backed by investments from Viking Global Investors, Bain Capital Life Sciences, Ziff Capital Partners, and the Bill & Melinda Gates Foundation, Affinivax is focused on the most challenging bacterial infections, both improving upon existing vaccines and providing vaccines for which there are no prevention strategies available today. The company's proprietary technology platform, called MAPS, enables the high affinity binding of protective polysaccharides and proteins in a single vaccine or immunotherapy to uniquely induce a broad and protective B and T cell immune response. The company's lead pneumococcal vaccine, in a partnership with Astellas Pharma, includes 24 pneumococcal serotypes, more than any other vaccine on the market or in clinical testing today. This vaccine has been demonstrated to be safe and highly immunogenic in healthy adults and is currently in Phase 2 clinical trials. In addition to targeting Streptococcus pneumoniae, the company is advancing a pipeline of MAPS vaccines targeting the most common hospital-associated infections (HAIs), and is also extending the utility of MAPS to a range of other potential applications, including vaccines and immunotherapies targeting viral diseases and cancer.

Key Contact
Steven B. Brugger
Funding Events

04/23/20 $120,000,000 Series B Bain Capital Life Sciences
Viking Global Investors
Ziff Capital Partners

Featured Reading